AKO-002

Last updated

AKO-002
Combination of
Psilocybin Serotonergic psychedelic
? Component Undisclosed specific plant bioactive
Clinical data
Other namesAKO002; Psilocybin/specific plant bioactive

AKO-002, or AKO002, is a combination of the non-selective serotonin receptor agonist and serotonergic psychedelic psilocybin and an undisclosed "specific plant bioactive" which is under development for the treatment of Alzheimer's disease. [1] [2] [3] While the "specific plant bioactive" in the combination and the action of this compound have not been disclosed, certain plant compounds, such as the β-carboline harmine in Banisteriopsis caapi , are reversible monoamine oxidase A (MAO-A) inhibitors and inhibit the metabolism of psychedelic tryptamines, in turn potentiating their effects. [4] [5] [6] AKO-002 is being developed by Akome Biotech. [1] [2] [3] As of March 2022, the drug is in the preclinical research stage of development. [1] [2]

Contents

See also

References

  1. 1 2 3 "AKO 002". AdisInsight. 8 March 2022. Retrieved 16 February 2025.
  2. 1 2 3 "Delving into the Latest Updates on AKO-002 with Synapse". Synapse. 23 January 2025. Retrieved 16 February 2025.
  3. 1 2 "Core One Labs Commences Development on Patent Pending Psychedelic Drug Formulation for the Treatment of Alzheimer's Disease". BioSpace. 6 May 2021. Retrieved 16 February 2025.
  4. ↑ Dos Santos RG, Hallak JE (November 2024). "Ayahuasca: pharmacology, safety, and therapeutic effects". CNS Spectrums: 1–9. doi: 10.1017/S109285292400213X . PMID   39564645.
  5. ↑ Egger K, Aicher HD, Cumming P, Scheidegger M (September 2024). "Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors". Cellular and Molecular Life Sciences. 81 (1): 395. doi:10.1007/s00018-024-05353-6. PMC   11387584 . PMID   39254764.
  6. ↑ Berlowitz I, Egger K, Cumming P (2022). "Monoamine Oxidase Inhibition by Plant-Derived β-Carbolines; Implications for the Psychopharmacology of Tobacco and Ayahuasca". Frontiers in Pharmacology. 13: 886408. doi: 10.3389/fphar.2022.886408 . PMC   9121195 . PMID   35600851.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.